Bicara Therapeutics (BCAX) EBIT (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of EBIT data on file, last reported at -$60.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 44.16% year-over-year to -$60.2 million; the trailing twelve-month figure through Mar 2026 stood at -$174.1 million (down 59.98% YoY), and the FY2025 full-year result was -$155.6 million, down 88.87% from the prior year.
• EBIT for Q1 2026 stood at -$60.2 million, down from -$41.1 million in the prior quarter.
• Across five years, EBIT topped out at -$9.5 million in Q3 2023 and bottomed at -$60.2 million in Q1 2026.
• The 4-year median for EBIT is -$26.6 million (2024), against an average of -$29.2 million.
• The widest annual swing landed in 2025, when EBIT slumped 171.81%; it then sank 44.16% in 2026.
• A 4-year view of EBIT shows it stood at -$13.7 million in 2023, then slumped by 94.62% to -$26.6 million in 2024, then plunged by 54.38% to -$41.1 million in 2025, then tumbled by 46.5% to -$60.2 million in 2026.
• The last three EBIT figures came in at -$60.2 million (Q1 2026), -$41.1 million (Q4 2025), and -$40.7 million (Q3 2025), per Business Quant data.

Peer Comparison